Microgynon 20 (Ethinylestradiol, Levonorgestrel)

Ethinylestradiol provides estrogenic activity that stabilizes the uterine lining, while levonorgestrel, a synthetic progestogen, suppresses the mid‑cycle surge of luteinizing hormone, thereby preventing ovulation. Together they also thicken cervical mucus and alter the endometrium, creating an environment that hinders sperm penetration and implantation.

The dosing schedule for Microgynon 20 is determined by the prescribing healthcare professional. Typically, one tablet is taken orally each day for 21 consecutive days followed by a pill‑free interval, but the exact regimen, including any missed‑dose instructions, must be individualized by the prescriber.

Microgynon 20 is classified as Pregnancy Category X, meaning it is contraindicated in pregnant women and must be discontinued if pregnancy occurs. While limited data exist for breastfeeding, most guidelines advise caution; the decision to use hormonal contraception while nursing should be made in consultation with a healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Microgynon 20. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Microgynon 20 contains 20 µg ethinylestradiol and 100 µg levonorgestrel, a low‑dose formulation that offers effective contraception with a reduced estrogen‑related risk profile. Compared with higher‑dose pills, it may have a lower incidence of estrogen‑related side effects, while maintaining comparable ovulation suppression. Choice of pill should consider individual risk factors, tolerability, and clinician preference.

Microgynon 20 tablets should be stored at ambient temperature below 25 °C, in their original blister pack, protected from moisture and direct light. Do not refrigerate or freeze the tablets. Keep them out of reach of children and discard any tablets that appear damaged or discolored.

Microgynon 20 is taken orally with water, preferably at the same time each day. A typical regimen involves one tablet daily for 21 days followed by a 7‑day pill‑free interval, during which withdrawal bleeding occurs. If a dose is missed, the patient should follow the specific missed‑dose instructions provided by the prescriber.

The most serious adverse events include venous thromboembolism, stroke, myocardial infarction, and severe allergic reactions such as anaphylaxis. These risks are higher in women who smoke, are over 35 years old, have a history of clotting disorders, or have uncontrolled hypertension. Prompt medical attention is required if symptoms of clotting or severe reactions develop.

Microgynon 20 is contraindicated in women who are pregnant or suspect they might be pregnant, have a history of thromboembolic disease, uncontrolled hypertension, severe liver disease, known or suspected breast cancer, or who are smokers over the age of 35. Individuals with known hypersensitivity to ethinylestradiol, levonorgestrel, or any tablet excipients should also avoid the product.